Press Releases
FITCI Seeks Consultant for Regional Entrepreneurship Economic Assessment
By
|
1/05/2024 – Frederick Innovative Technology Center, Inc. (FITCI) is a business incubator and accelerator designed to cultivate entrepreneurship in Frederick, Maryland. It offers coaching, connections, access to capital, and customers … Read more
Meridian BioGroup acquired by Pace® Life Sciences
Expanding Regulatory, Compliance, and Validation Capabilities to the Biotechnology and Pharmaceutical Markets
By
Meridian BioGroup
|
We are excited to announce, that Meridian BioGroup has been acquired by Pace® Life Sciences. The acquisition allows Pace® to provide regulatory and quality consulting services to support clients throughout the … Read more
A single injection hepatitis B cure attracts international attention
Dr. Yong-Yuan Zhang presents in Paris, Seoul, and Washington DC in 2022
By
April Bartel
|
Frederick, MD – HBVtech, a biopharma startup company within the Frederick Innovation Technology Center (FITCI), is garnering international attention for its work creating a single-dose injection-based hepatitis B cure. Founder … Read more
AFFORDABLE POINT OF SERVICE HEALTHCARE ACCESS COMES TO MARYLANDERS
MARYLAND BUSINESSES PARTNERSHIP TO PROVIDE TELEHEALTH PLATFORM TO MITIGATE HEALTH INEQUITY
By
Ashok Kapur, Hawkeye MedTech
|
Columbia, MD, July 18, 2022 – Hawkeye Med Tech, Inc, a Maryland Medtech company has partnered with the Kiosk Group, Ltd,. to produce one-of-a-kind Portable TotalCare Telehealth StationTM or PTTS. PTTS is … Read more
Mesa Science Associates Receives Grant to Study Marfan Syndrome Treatment
Development of Cobinamide as a Novel Treatment for Aortic Aneurysms of Marfan Syndrome: Phase I Pharmacokinetic Studies
By
Mesa Associates, Inc.
|
Mesa Science Associates Inc. (MSA) received a Phase I Small Business Innovative Research Grant (SBIR) from the National Institutes of Health (NIH) entitled “Development of Cobinamide as a Novel Treatment … Read more
FITCI Grad BioFactura Announces Activation of a $15.9M Contract Option
Smallpox Biodefense Therapeutic, contract valued at up to $68.2 million
By
Darryl Sampey, Ph.D., CEO
|
FREDERICK, MARYLAND, JULY 14, 2022: BioFactura today announced its second contract option activation of $15.9 million from the Biomedical Advanced Research and Development Authority (BARDA) to advance development of an … Read more
TEDCO Invests in FITCI Member, Alirtify, a Rural Maryland Pre-Seed Company
Alirtify is an intelligence-gathering platform
By
Tammi Thomas, Chief Marketing & Communications Officer, TEDCO tthomas@tedco.md
|
July 5, 2022—TEDCO, Maryland’s economic engine for technology companies (and a FITCI founding partner), announced today that its Rural Business Innovation Initiative (RBII) made a $25,000 investment in Alirtify, an intelligence-gathering platform based … Read more
THERADAPTIVE: shaping the future of regenerative medicine at military treatment facilities
Advanced theraputic can mean the difference between amputation and limb preservation
By
The Geneva Foundation
|
Theradaptive is shaping the future of regenerative medicine with a new platform to deliver therapeutics that promote targeted native tissue repair. Their lead therapeutic, AMP2, is applied to an orthopedic … Read more
Theradaptive Secures Third FDA Breakthrough Designation for Spinal Fusion
Theradaptive’s technology re-grows bone
By
Serena Lertora serena.lertora@theradaptive.com
|
FREDERICK, Md. and BOSTON, June 22, 2022 /PRNewswire/ — Theradaptive, a privately held biopharmaceutical company pioneering a new class of regenerative implants announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough … Read more
Veralox Therapeutics Announces Favorable Results of Phase 1 Studies of VLX-1005
A novel small molecule 12-LOX inhibitor, awarded Fast Track designation by US Food and Drug Administration
By
|
for Treatment of Heparin-Induced Thrombocytopenia FREDERICK, Md., June 13, 2022 /PRNewswire/ — Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat serious immuno-inflammatory diseases with significant unmet medical needs, … Read more
